ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

The company expects its preliminary third-quarter sales results to remain unchanged.

Rhea-AI Summary

ImmuCell (ICCC) expects to release unaudited financial results for the quarter ended September 30, 2023, after the November 13 market close.

The company expects to file its quarterly Form 10-Q that evening. It anticipates no change to the preliminary third-quarter sales results disclosed on October 5. A call to review the financial results is scheduled for November 14 at 9:00 a.m. ET.

Key Figures

Results announcement date: November 13, 2023

Results announcement date

November 13, 2023

Unaudited third-quarter financial results expected after market close

Key Terms

form 10-q, subclinical mastitis

2 terms

form 10-q regulatory

"file its Quarterly Report on Form 10-Q"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

subclinical mastitis medical

"a novel treatment for subclinical mastitis in dairy cows"

An inflammation of the udder in dairy animals that shows no obvious signs like swelling or fever but is detectable by elevated white blood cells or bacterial counts in milk. It matters to investors because it can quietly reduce milk yield and quality, increase testing and treatment costs, and lead to regulatory or product-quality problems for food and dairy companies; think of it as a hidden engine problem that lowers performance over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PORTLAND, Maine, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2023 after the market closes on Monday, November 13, 2023.

The Company expects to file its Quarterly Report on Form 10-Q after the market closes on Monday, November 13, 2023. The Company anticipates no change to the preliminary sales results for the third quarter of 2023 that were disclosed on October 5, 2023.

The Company has scheduled a conference call the next morning, Tuesday, November 14, 2023, at 9:00 AM ET to review its third quarter financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until November 21, 2023 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #5077962.

Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company, after the market closes on Monday, November 13, 2023.

About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense^®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain^®, a novel treatment for subclinical mastitis in dairy cows with a no milk discard claim that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.

Contacts:	Michael F. Brigham, President and CEO
	ImmuCell Corporation
	(207) 878-2770
	Joe Diaz, Robert Blum and Joe Dorame
	Lytham Partners, LLC
	(602) 889-9700
	iccc@lythampartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors join ImmuCell's third-quarter 2023 earnings call or hear the replay?

The call is scheduled for November 14, 2023, at 9:00 a.m. ET; callers can dial (844) 855-9502 toll free or (412) 317-5499 internationally. A replay will be available until November 21 at (877) 344-7529 toll free or (412) 317-0088 internationally, using access code 5077962.